首页> Cancer prevention research (Philadelphia, Pa.)> Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1.

Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1.

导出 OA

翻译打印收藏纠错

第一作者： Kotha,Subbaramaiah

作者： Kotha,Subbaramaiah ; Louise R,Howe ; Xi Kathy,Zhou ; Peiying,Yang ; Clifford A,Hudis ; Levy,Kopelovich ; Andrew J,Dannenberg

DOI 10.1158/1940-6207.CAPR-22-0204

PMID 35652223

发布时间 2024-12-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Cancer prevention research (Philadelphia, Pa.)

2022年15卷6期

411页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览2

点击下载本期目录封面

Cancer prevention research (Philadelphia, Pa.)

2022年15卷6期

411页

检索历史清除

Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1.

Cancer prevention research (Philadelphia, Pa.)

相似文献

Cancer prevention research (Philadelphia, Pa.)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1.

Cancer prevention research (Philadelphia, Pa.)

相似文献

Cancer prevention research (Philadelphia, Pa.)

相关期刊

检索历史清除